AtriCure to Announce Third Quarter 2024 Financial Results
08 Octubre 2024 - 7:00AM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments and therapies for atrial fibrillation (Afib), left
atrial appendage (LAA) management, and post-operative pain
management, today announced that it will release its third quarter
2024 financial results on Tuesday, October 29, 2024.
AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on
Tuesday, October 29, 2024, to discuss its third quarter 2024
financial results. Those interested in listening to the conference
call should register online using this link. Participants are
encouraged to register more than 15 minutes before the start of the
call. A live and replay version of the audio webcast will be
available at
https://ir.atricure.com/events-and-presentations/events.
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 37
million people worldwide. Electrophysiologists, cardiothoracic and
thoracic surgeons around the globe use AtriCure technologies for
the treatment of Afib, reduction of Afib related complications and
post-operative pain management. AtriCure’s Isolator® Synergy™
Ablation System is the first medical device to receive FDA approval
for the treatment of persistent Afib. AtriCure’s AtriClip® Left
Atrial Appendage Exclusion System products are the most widely sold
LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is
a minimally invasive procedure that provides a lasting solution for
long-standing persistent Afib patients. AtriCure’s cryoICE
cryoSPHERE® probes are cleared for temporary ablation of peripheral
nerves to block pain, providing pain relief in cardiac and thoracic
procedures. For more information, visit AtriCure.com or follow us
on X (formerly Twitter) @AtriCure.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241008614077/en/
Angie Wirick AtriCure, Inc. Chief Financial Officer (513)
755-5334 awirick@atricure.com
Marissa Bych Gilmartin Group Investor Relations
marissa@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
AtriCure (NASDAQ:ATRC)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
